ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ALKS Stock Price » ALKS Stock News

Alkermes Share News

 Alkermes (mm) Stock Price
ALKS Stock Price
 Alkermes (mm) Stock Chart
ALKS Stock Chart
 Alkermes (mm) Stock News
ALKS Stock News
 Alkermes (mm) Company Information
ALKS Company Information
 Alkermes (mm) Stock Trades
ALKS Stock Trades

Eli Lilly Type-1 Diabetes Drug Fails Trial Efficacy Endpoint

DOW JONES NEWSWIRES Eli Lilly & Co. (LLY) and its partner in licensing diabetes-drug candidate teplizumab said the treatment failed to reach the main efficacy goal a late-stage study. As a results, Lilly and MacroGenics Inc. suspended further enrollment and dosing of patients in two other ongoing clinical trials of the treatment effect in type-1 diabetes. Teplizumab, which the companies license from PDL BioPharma Inc. (PDLI), was being tested to treat newly diagnosed type-1 diabetes, the less-common type of the disease. The treatment was meant to slow its progression. Gwen Krivi, a Lilly executive in diabetes product development, called the drug's failure to reach the primary endpoint "obviously disappointing. She said the two companies will be considering all options for teplizumab. Under the licensing arrangement, Lilly agreed to pay PDL BioPharma fees during testing of teplizumab and would pay royalties on sales if the drug is approved. The trial results follow other another disappointment for Lilly on a diabetes drug-candidate earlier this week. The Food and Drug Administration held off on approving the company's long-acting version of diabetes drug Byetta, requesting more testing and data analysis. Eli Lilly is developing the drug with Amylin Pharmaceuticals Inc. and Alkermes Inc. (ALKS). The approval was widely expected. Lilly shares were down 0.2% at $35.95 in after-hours trading, while PDL closed the regular session Wednesday up 2.2% at $5.59 and wasn't active after the close. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Alkermes (ALKS)
DateTimeHeadline
04/23/201517:18:42Statement of Changes in Beneficial Ownership (4)
04/23/201517:13:54Statement of Changes in Beneficial Ownership (4)
04/23/201516:00:00Alkermes to Host Conference Call to Discuss First Quarter 2015...
04/17/201517:45:25Statement of Changes in Beneficial Ownership (4)
04/17/201517:29:38Statement of Changes in Beneficial Ownership (4)
04/17/201517:21:19Statement of Changes in Beneficial Ownership (4)
04/17/201517:14:49Statement of Changes in Beneficial Ownership (4)
04/16/201516:31:50Amended Current Report Filing (8-k/a)
04/14/201516:37:08Additional Proxy Soliciting Materials (definitive) (defa14a)
04/14/201516:36:15Proxy Statement (definitive) (def 14a)
04/14/201508:55:41Alkermes - The Underappreciated Biopharmaceutical
04/13/201507:16:55Current Report Filing (8-k)
04/13/201507:00:00Alkermes to Present Preclinical Data on Novel Selective Effector...
04/11/201510:14:03A New Drug Could Halt Weight Gain in Patients Taking These Antipsychotics
04/07/201518:54:05Statement of Changes in Beneficial Ownership (4)
04/06/201508:47:42Alkermes antipsychotic drug shows durable efficacy and beneficial...
04/06/201507:00:00Alkermes Announces Positive Topline Results from Complete Six-Month...
04/01/201517:51:53Statement of Changes in Beneficial Ownership (4)
04/01/201517:47:35Statement of Changes in Beneficial Ownership (4)
03/24/201517:17:30Statement of Changes in Beneficial Ownership (4)

Alkermes and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad